Nussbaumer Oliver, Koslowski Michael
GammaDelta Therapeutics Ltd, London, UK.
Immunooncol Technol. 2019 Jun 26;1:3-10. doi: 10.1016/j.iotech.2019.06.002. eCollection 2019 Jul.
The recent successes of chimeric antigen receptor T cells in the treatment of hematological malignancies have clearly led to an explosion in the field of adoptive cell therapy for cancer. Current efforts are focused on the translation of this exciting technology to the treatment of solid tumors and the development of allogeneic 'off-the-shelf' therapies. γδ T cells are currently gaining considerable attention in this field as their unique biology and established role in cancer immunosurveillance place them in a unique position to potentially overcome these challenges in adoptive cell therapy. Here, we review the relevant aspects of the function of γδ T cells in cancer immunity, and summarize clinical observations and clinical trial results that highlight their emerging role as a platform for the development of safe and effective cancer immunotherapies.
嵌合抗原受体T细胞在血液系统恶性肿瘤治疗中的近期成功,显然引发了癌症过继性细胞治疗领域的迅猛发展。当前的努力集中于将这项令人振奋的技术转化用于实体瘤治疗以及开发异基因“现成可用”疗法。γδ T细胞目前在该领域正受到广泛关注,因为其独特的生物学特性以及在癌症免疫监视中已确立的作用,使其在过继性细胞治疗中处于有可能克服这些挑战的独特地位。在此,我们综述γδ T细胞在癌症免疫中功能的相关方面,并总结突出其作为安全有效的癌症免疫疗法开发平台的新兴作用的临床观察和临床试验结果。